Sanofi positive over Multaq as FDA and EMA probes are extended

via pharmatimes.com

Sanofi told PharmaTimes World News that it is working with the EMA and the FDA to provide the agencies with a full analysis of the data from PALLAS. The firm notes that some 400,000 patients have been treated with Multaq worldwide and considers that its benefit-risk profile "remains positive in its approved indication".

Posted via email from Jack's posterous